當(dāng)前位置：   首頁(yè) > 需求大廳

 >  特色服務(wù) 

 >  信息服務(wù) 

求購(gòu)國(guó)內(nèi)外雜質(zhì)或標(biāo)準(zhǔn)品產(chǎn)品目錄 長(zhǎng)期有效 要求： 1.要求為EXCEL格式，并且是可編輯的。 2.內(nèi)容包括產(chǎn)品英文名、中文名、CAS號(hào)、分子式、用途、規(guī)格、廠家信息等。注意：廠家必須是實(shí)際生產(chǎn)廠家而不是銷(xiāo)售廠家，提供信息內(nèi)容必須屬實(shí)，字段越多越詳細(xì)越好 3.我們已有的廠家產(chǎn)品信息如下，提供以下信息不能中標(biāo)。 國(guó)內(nèi)：常州美泰 臨沂盛鑫 北京金寶 成都生物 成都貝斯特 成都曼斯特 上海同田 和云南西力 國(guó)外：英國(guó)LGC 加拿大TRC 歐洲EP標(biāo)準(zhǔn)品 美國(guó)CATO 美國(guó)CRS 英國(guó)PCL 日本JP標(biāo)準(zhǔn)品 4.賞金按照按照目錄的珍稀程度、信息數(shù)量 來(lái)商議。 本需求托管賞金為零元，如果您要提供信息，請(qǐng)投稿時(shí)留下您的聯(lián)系方式如:QQ號(hào)碼。我們會(huì)主動(dòng)與您聯(lián)系，價(jià)格私下商議。本需求長(zhǎng)期有效。   [更多]

必須同時(shí)滿(mǎn)足以下幾條： 1.必須提交中標(biāo)來(lái)源文件，包括公告信息，來(lái)源網(wǎng)址。 2.具體中標(biāo)品種信息（產(chǎn)品中標(biāo)價(jià)等）不是網(wǎng)上公布的（即大家都可以查詢(xún)到的），是需要登錄各省耗材系統(tǒng)才可以下載的數(shù)據(jù)。 4.以附件的形式提交中標(biāo)文件及鏈接，中標(biāo)文件必須整理為EXCEL格式，一個(gè)中標(biāo)文件算一條信息。 具體的薪酬計(jì)算方法以和我溝通協(xié)商后的結(jié)果為準(zhǔn)。   [更多]

我需要全國(guó)各醫(yī)院的銷(xiāo)售數(shù)據(jù)，尋找可以長(zhǎng)期提供醫(yī)院銷(xiāo)售數(shù)據(jù)的合作者，醫(yī)院銷(xiāo)售數(shù)據(jù)要求具體到某個(gè)醫(yī)院并且數(shù)據(jù)真實(shí)可靠。 如果能長(zhǎng)期提供該數(shù)據(jù)的，請(qǐng)投稿，具體價(jià)格等事宜單獨(dú)聯(lián)系。   [更多]

防粘連產(chǎn)品屬于三類(lèi)醫(yī)療器械，現(xiàn)需行業(yè)終端銷(xiāo)售數(shù)據(jù)、市場(chǎng)分布等信息。價(jià)格另議。   [更多]

pdf，清晰可見(jiàn)   [更多]

投稿后詳談，只要您有數(shù)據(jù)資源，一切都可以談。   [更多]

加巴噴丁原料藥和加巴噴丁片的藥典標(biāo)準(zhǔn)。USP39-NF34   [更多]

EP10.0: 1. 昔萘酸沙美特羅Salmeterol Xinafoate 2. 對(duì)氨基水楊酸鈉Sodium Aminosalicylate Dihydrate 3. 亞胺培南Imipenem monohydrate 4. 西司他丁鈉Cilastatin sodium 5. 制霉菌素Nystatin 6. ω-3 脂肪酸甘油三酯Omega-3-Acid Triglycerides 7. 噻托溴銨一水合物Tiotropium Bromide Monohydrate 8. 硫酸沙丁胺醇Sulbutamol Sulphate 文獻(xiàn)： 1、Preventative approaches for neurophathy in diabetes with Alpha-lipoic Acid 2奧硝哩 在人體 內(nèi)的代謝與排泄研究 杜江 波 ” , 尤 天庚 ’ , 陳笑艷 ’ , 鐘 大放 ” 1. 中國(guó)科學(xué)院上海藥物研究所 , 上海 2 0 1 2 03 2 . 上海東方醫(yī)院 , 上海 2 0 01 2 0   [更多]

1.Myopia Control with Bifocal Contact Lenses:?A Randomized Clinical Trial 2.The Role of Atropine Eye Drops in Myopia Control 4. Myopia Control: A Review 7. Efficacy of 1%?atropine?eye drops in retarding progressive axial myopia in Indian eyes 8.Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia 9.Current approaches to myopia control 10.Atropine?for the Prevention of Progression in Myopia - Data, Side Effects, Practical Guidelines 13. Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia. 18. The treatment of myopia with?atropine?and bifocals. A long-term prospective study 19. Inhibitory effects of apomorphine and?atropine?and their combination on myopia in chicks 20. The penetration and distribution of topical?atropine?in animal ocular tissues. 21. Treatment outcomes of?myopic?anisometropia with 1%?atropine: a pilot study 23. Does?atropine?use increase intraocular pressure in?myopic?children? 24. Atropine?use for the prevention of myopia progression 25. Allergic reactions to?atropine?eye drops for retardation of progressive myopia in children. 29. Maximum?atropine?dose without clinical signs or symptoms. 31. Atropine?and bifocals can slow the progression of myopia in children. 33. Prevention of myopia onset with 0.025%?atropine?in premyopic children 35. The long-term results of using low-concentration?atropine?eye drops for controlling myopia progression in schoolchildren. 37. Prevention of myopia progression with 0.05%?atropine?solution.   [更多]

1、American Conference of Governmental Industrial Hygienists TLVs and BEIs. Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati, OH, 2008, 2、內(nèi)容：Totsuka K，F(xiàn)urukawa M，F(xiàn)uruya N，et al. PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial （3）.45th Intersci Conf Antimicrob Agents Chemother（ICAAC）（Dec 16-19. Washington，D.C.），2005，Abst L-579標(biāo)題 PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial； 3、PK–PD analysis of tebipenem pivoxil in clinical trials for pediatric patients. Jpn J Chemother. 2009;57(S-1):186–91. 4、Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. González MA1, Straughan AB. 5、Single dose study of the bioequivalence of two sustained-release theophylline formulations. Contreras J, Pérez N, González R, Ontivero E, López M. Arzneimittelforschung. 1998 Mar;48(3):259-62. 6、National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information., AD277-689 7、Graul, A.; Castaner, J.; Atorvastatin Calcium. Drugs Fut 1997, 22, 9, 956. 8、Formulation And Evaluation of Topical Aceclofenac Gel Using Different Gelling Agent（JAPAN PATEL1*, BRIJESH PATEL1, HARDEEPSINGH BANWAIT1, KAUSHAL PARMAR1,MANISH PATEL2 Department of Pharmaceutics, Sat Kaival College of Pharmacy, Sarsa, Anand, Gujarat, India Nootan Pharmacy College, Visnagar, Gujarat, India） 9、NCCN pediatric neuroblastoma practice guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Dec;10(12):1813-22 10、Preliminary studies on toxic effects of some vulcanizing accelerators 11、Dose Dumping Dose dumping is an increased concern with drugs manufactured as modified-release (MR) formulations, that is, where drug   [更多]